Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is positioned favorably due to its promising development of stenoparib, which has demonstrated a median overall survival exceeding 25 months in its Phase 2 trial for patients with advanced recurrent ovarian cancer. The company's proprietary Drug Response Predictor (DRP) technology enhances patient selection, which is expected to improve clinical outcomes and address significant unmet medical needs in oncology. Furthermore, the consistent upward adjustment in 12-month price targets—indicative of a positive net present value (NPV) analysis—highlights the attractive valuation of the company amidst its ongoing clinical advancements.

Bears say

Allarity Therapeutics has reported a net loss of $2.8 million, resulting in an earnings per share (EPS) of $(0.19), which indicates financial performance that fell short of prior estimates. The company's balance sheet presents significant liquidity risks, exacerbated by the ongoing uncertainty regarding the safety and efficacy of its product candidates, specifically stenoparib, in clinical trials and regulatory approvals. Furthermore, a multitude of external factors, such as evolving investor sentiment towards biotechnology stocks and potential challenges in commercialization and reimbursement, compounds the negative outlook for Allarity Therapeutics's stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.